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Abstract
Background: Acute respiratory tract infections (ARTI) are among the most frequent reasons for consultations in
primary care. Although predominantly viral in origin, ARTI often lead to the prescription of antibiotics for ambulatory
patients, mainly because it is difficult to distinguish between viral and bacterial infections. Unnecessary antibiotic use,
however, is associated with increased drug expenditure, side effects and antibiotic resistance. A novel approach is to
guide antibiotic therapy by procalcitonin (ProCT), since serum levels of ProCT are elevated in bacterial infections but
remain lower in viral infections and inflammatory diseases.
The aim of this trial is to compare a ProCT-guided antibiotic therapy with a standard approach based on evidence-based
guidelines for patients with ARTI in primary care.
Methods/Design: This is a randomised controlled trial in primary care with an open intervention. Adult patients judged
by their general practitioner (GP) to need antibiotics for ARTI are randomised in equal numbers either to standard
antibiotic therapy or to ProCT-guided antibiotic therapy. Patients are followed-up after 1 week by their GP and after 2
and 4 weeks by phone interviews carried out by medical students blinded to the goal of the trial.
Exclusion criteria for patients are antibiotic use in the previous 28 days, psychiatric disorders or inability to give written
informed consent, not being fluent in German, severe immunosuppression, intravenous drug use, cystic fibrosis, active
tuberculosis, or need for immediate hospitalisation.
The primary endpoint is days with restrictions from ARTI within 14 days after randomisation. Secondary outcomes are
antibiotic use in terms of antibiotic prescription rate and duration of antibiotic treatment in days, days off work and days
with side-effects from medication within 14 days, and relapse rate from the infection within 28 days after randomisation.
Discussion: We aim to include 600 patients from 50 general practices in the Northwest of Switzerland. Data from the
registry of the Swiss Medical Association suggests that our recruited GPs are representative of all eligible GPs with
respect to age, proportion of female physicians, specialisation, years of postgraduate training and years in private practice.
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Background
Acute respiratory tract infections (ARTI) are among the
most frequent reasons for seeking ambulatory care [1].
ARTI in the context of this study include common cold,
pharyngitis, tonsillitis, rhinosinusitis, tracheo-bronchitis,
otitis media, acute exacerbations of asthma and of chronic
obstructive pulmonary disease (COPD), and community
acquired pneumonia. As much as 75% of antibiotics are
prescribed for ARTI, despite the mainly viral origin [2-8].
Criteria often used in clinical practice to distinguish bac-
terial from viral infections of the respiratory tract include
fever, dyspnea, purulent sputum, chest X-ray infiltrates, C-
reactive protein, leucocyte count, and recovery of a patho-
gen from the respiratory tract or from blood cultures [9].
However, these are all non-specific symptoms and hence
differentiation between viral and bacterial ARTI remains a
diagnostic challenge [10]. Moreover, when antibiotic
treatment is initiated, the optimal duration of antibiotic
treatment for ARTI has not been determined [11,12]. In
community acquired pneumonia an antibiotic treatment
duration of 10 to 14 days is generally recommended,
although data from intervention trials are lacking [13].
Unnecessary antibiotic use (i.e. number of prescriptions
and duration of treatment) for ARTI not only increases
drug expenditure [14] and the risk of adverse events [15],
but also results in selection of resistant microorganisms
[16]. Thereby, it constitutes an important public health
problem [17]. For combating the increase in resistant
infections a decrease of the excess antibiotic use is para-
mount [18]. There are only few intervention studies that
have reported a successful reduction of antibiotic use in
ambulatory care [19-25]. Most of these studies were not
conducted in ARTI or have methodological limitations.
A novel approach to guide antimicrobial therapy is to pre-
scribe antibiotics based on the level of biomarkers, specif-
ically, calcitonin precursors, including procalcitonin
(ProCT). Circulating levels of ProCT are elevated in sys-
temic bacterial infections but remain relatively low in
viral infections and inflammatory diseases [26,27]. In
severe bacterial infections the use of ProCT significantly
improves the sensitivity and specificity of the clinical diag-
nosis of infection [28]. A recent systematic review and
meta-analysis found that ProCT is superior compared to
C-reactive protein for the diagnosis of bacterial infections
[29]. Most recently, we gathered evidence that both anti-
biotic prescription and treatment duration could be safely
and markedly reduced in hospitalised patients with lower
respiratory tract infections using ProCT-stewardship
[30,31]. In successfully treated infections, circulating
ProCT levels decrease in a log-linear pattern and have a
plasma half life of 24 hours. In contrast, prolonged ele-
vated plasma ProCT levels indicate adverse outcome
[26,27].
Several studies indicate that the main reasons for antibi-
otic prescription in ambulatory patients with ARTI are
non-medical and related to the physician-patient relation-
ship, patients' expectations and beliefs about the benefit
of antibiotics [32,33]. Thus, in theory a reduction of anti-
biotic prescriptions and duration can also be achieved by
the implementation of guidelines [34]. However, in prac-
tice physician education and guidelines dissemination for
ARTI management usually show no clinically relevant
effect [25,35,36].
Methods/Design
Study aims
The objective of this trial is to evaluate, if a ProCT-guided
diagnostic and therapeutic strategy leads to a similar out-
come and reduced total antibiotic use for patients with
ARTI in primary care compared to a standard approach
recommended by current guidelines.
Study design and setting
This is a prospective, randomised, controlled, open inter-
vention trial in primary care with appropriate power cal-
culation. Adult patients suffering from ARTI, for whom
the treating general practitioner (GP) decides to give anti-
biotic treatment on the basis of evidence-based guide-
lines, are randomised to routine antibiotic therapy or
ProCT-guided antibiotic treatment. The pathway by which
patients are recruited and followed-up is given in Figure 1.
Ethical considerations
The Ethics Committee of the University Hospital Basel,
Switzerland, approved the study protocol which is in
compliance with the Helsinki Declaration. Written
informed consent was obtained from all participating
GPs. All recruited patients have to give written informed
consent.
The trial is supervised by an independent monitoring
board that is not involved in the design and conduct of
the trial, or in the recruitment of patients. The board con-
sists of a general internist in primary care, an infectious
disease specialist and a pneumologist.
Participants
We invited all GPs of two cantons (Basel-Stadt and Basel-
Land) in the Northwest of Switzerland to participate in
the trial. Of 345 GPs contacted, 53 working at 50 practices
gave written informed consent and were included (Figure
2).
From December 2004 GPs included in this study consec-
utively screen all eligible adults (aged 18 years or older)BMC Family Practice 2005, 6:34 http://www.biomedcentral.com/1471-2296/6/34
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Summary of the trial design Figure 1
Summary of the trial design.
ARTI >1 to <28 days, no antibiotics in previous 28 days, AND need
for antibiotics as judged by the GP 
Randomisation
Standard group ProCT group
Initiation of antibiotic treatment according to 
evidence-based guidelines
Day 0 Initiation of antibiotic treatment according to 
evidence-based guidelines & ProCT level (µg/l). 
Recommendations:
<0.1 NO antibiotic treatment! 
0.1-0.25 no antibiotic treatment
>0.25 antibiotic treatment
Recommendations according to ProCT level (µg/l); 
Initiate, stop or continue antibiotics based on the 
same cut-offs as defined above
Day 1 for patients not on antibiotics: Follow-up by 
GP with re-measuremento f ProCT
Day 3 for patients on antibiotics: Follow-up by GP 
with re-measuremento f ProCT Continuation of antibiotic therapy according to 
type of antibiotic and guideline-recommendations
for treatment duration;
Additional follow-up by GP according to clinical
judgement
Day 7 for all patients: Follow-up by GP with final measurement of 
ProCT
Day 28 Phone Interview II 
Day 14 Phone Interview I 
Patients with ARTI & exclusion criteria
Fulfilled inclusion criteria, no exclusion criteria & informed consent
Baseline data collection in all eligible individualsBMC Family Practice 2005, 6:34 http://www.biomedcentral.com/1471-2296/6/34
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with symptoms (first experienced within the previous 28
days) of acute infection of the respiratory system. Inclu-
sion criteria for patients are a consultation for common
cold, pharyngitis, tonsillitis, rhinosinusitis, tracheo-bron-
chitis, otitis media, influenza, acute exacerbations of
asthma or COPD, or community acquired pneumonia,
the GPs intention to prescribe antibiotics on the basis of
evidence-based guidelines, and written informed consent.
Exclusion criteria for patients are antibiotic use in the pre-
vious 28 days, intravenous drug use, psychiatric disorders
or inability to give written informed consent, not being
fluent in German, severe immunosuppression (e.g. in
HIV-infection, after solid organ transplantation or under
chemotherapy), cystic fibrosis, active tuberculosis, and
need for immediate hospitalisation. Study practices com-
plete the trial after including 20 patients or at the antici-
pated end of the trial in December 2005.
Randomisation
Allocation of patients to either treatment group is con-
cealed by using a centralised randomisation procedure
with a computer generated list produced by an independ-
ent statistician otherwise not involved in the trial. Ran-
domisation is stratified by GP practice.
Interventions
All participating GPs received instructions about the pro-
tocol and the details of the clinical trial in a 1-hour semi-
nar. They were asked to consecutively enrol all patients
with ARTI that they judge to be in need of antibiotic treat-
ment according to guidelines. They were told how to call
the central randomisation unit, and how to fill in the nec-
essary study forms.
Flow diagram of recruited general practitioners Figure 2
Flow diagram of recruited general practitioners.
132 GPs responded (38%) 
67 GPs interested  65 GPs not interested 
14  GPs refused informed consent or
      dropped out
13  refused because of work-load
 1  dropped out because of illness
Seminar about procalcitonin,
evidence-based guidelines for ARTI, 
and study introduction 
(December 9 ’04 and January 6 ’05)
53 GPs from 50 practices gave written informed consent and participate in the study 
345 eligible GPs from canton Basel 
with invitation letter BMC Family Practice 2005, 6:34 http://www.biomedcentral.com/1471-2296/6/34
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Evidence-based guidelines
HCB and MB developed guidelines for the management
of ARTI based on evidence-based US-position papers
which were endorsed by the Centers for Disease Control
and Prevention, the American Academy of Family Medi-
cine, the American College of Physicians, and the Infec-
tious Disease Society of America [37-42]. We
systematically searched MEDLINE and the Cochrane
Library to update this evidence with recent controlled
clinical trials. A panel of local primary care providers,
infectious disease experts, and clinical epidemiologists
reviewed the guidelines and made suggestions for adapta-
tion to local conditions. We distributed the guidelines as
a booklet (see http://www.bice.ch/publications/reports)
and presented them in a 2-hour seminar to all participat-
ing GPs.
Procalcitonin test
We measure ProCT by using a newly developed time-
resolved amplified cryptate emission (TRACE) technology
assay (Kryptor PCT, Brahms, Henningsdorf, Germany).
This assay is based on a sheep polyclonal antibody against
calcitonin and a monoclonal antibody against katacalcin,
which bind to the calcitonin and katacalcin sequence of
calcitonin precursor molecules. The assay has an
improved functional assay sensitivity of 0.06 µg/l – i.e.,
three to ten fold above normal mean values. Assay time is
19 min with 20–50 µl of plasma or serum. The test is per-
formed at the central laboratory of the University Hospital
Basel, and results can be communicated to participating
GPs within 2–4 h depending on the location of the
practice.
Data collection and management
We obtained baseline data on all eligible GPs from the
registry of the Swiss Medical Association. These data sug-
gested that included GPs are representative of all eligible
GPs with respect to age, years in private practice, years of
postgraduate training, years since diploma, specialisation,
and percentage of female physicians (Table 1).
When a participating GP intends to give antibiotic treat-
ment to an eligible patient based on clinical criteria and
the patient gives written informed consent, the GP calls
the study centre and the patient is randomly allocated to
one treatment group or the other. The GP then takes a
blood sample from the patient and sends it by courier
service to the laboratory of clinical chemistry at the Uni-
versity Hospital Basel. This laboratory measures ProCT in
all patients. Additionally, the GP documents patient base-
line data on signs and symptoms, diagnostic procedures,
diagnosis, co-morbidity and prescribed medication.
Where patients are randomised to the ProCT-arm, GPs
will be informed about ProCT results and given recom-
mendations about appropriate antibiotic therapy within
2–4 h after the blood is taken depending on the location
of the practice. A cut-off ProCT level of 0.1 µg/l is used to
rule out a bacterial respiratory tract infection. This value is
identical to the cut-off used for the evaluation of patients
in the emergency department of the University Hospital
Basel [30]. In patients with a ProCT level below 0.1 µg/l,
the diagnosis of a bacterial respiratory tract infection is
considered highly unlikely, and the GP is encouraged to
look for viral or alternative causes. Accordingly, the use of
antibiotics is discouraged. In patients with a ProCT level
above 0.25 µg/l, a bacterial respiratory tract infection is
considered the most likely diagnosis and the use of anti-
biotics is recommended. For ProCT levels from 0.1 to 0.25
µg/l, a bacterial infection is unlikely and antibiotic treat-
ment is not advocated.
The GP then informs the patient about antibiotic treat-
ment by phone. Patients in whom antibiotics are given
will be asked to use a delayed prescription or to come back
to the practice to pick up the antibiotic there. For patients
Table 1: Baseline characteristics of general practitioners
Study GPs All eligible GPs
n = 53 n = 345
Age – median [IQR] 51 [42 – 55] 53 [47 – 58]
Female physicians – n (%) 9 (17) 64 (19)
Specialisation
General medicine – n (%) 25 (47) 188 (54)
Internal medicine – n (%) 26 (49) 148 (43)
Other – n (%) 2 (3.8) 9 (2.6)
Years in private practice – median [IQR] 15 [6.2 – 20] 16 [9.0 – 23]
Years of postgraduate training – median [IQR] 8.8 [7.7 – 9.7] 8.9 [7.6 – 11]
Years since diploma – median [IQR] 25 [15 – 29] 26 [14 – 31]BMC Family Practice 2005, 6:34 http://www.biomedcentral.com/1471-2296/6/34
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in whom antibiotics are withheld based on ProCT levels
of 0.25 µg/l or below, a follow-up measurement of ProCT
within 24 hours is mandatory. If the ProCT level on this
initial follow-up is >0.25 mg/l or if it has increased by
more than 50% from its initial value without clinical
improvement of the patient, the use of antibiotics is
recommended.
In the ProCT group, all patients treated with antibiotics
will be reassessed at Day 3. Discontinuation of antibiotic
treatment is recommended if the ProCT level has
decreased at least to 0.25 µg/l or below.
GPs draw blood samples and document therapy at each
follow-up visit. They also collect information on days
with restrictions and days off work at 1 week (6–8 days)
after randomisation for all patients. Medical students,
blinded to treatment allocation of patients and to the goal
of the trial, will conduct standardised follow-up
interviews at 14 and 28 days by phone. The patient flow
will be monitored according to current guidelines and in
agreement with the CONSORT statement [43]. We will
use Teleform® (Cardwell, Cardiff, GB) for data entry.
Adverse events
Any serious adverse event is reported by fax to the princi-
ple investigator within 24 hours. We define a severe event
independent of group allocation as hospitalisation for
any reason, any complication related to infection such as
sepsis, abscess etc., or allergic reaction due to the received
therapy, or death that occurs within 28 days following the
inclusion of the patient into the trial.
Outcomes and hypotheses
The primary outcome is days with restrictions from ARTI
within 14 days after randomisation. Secondary outcomes
are antibiotic use in terms of antibiotic prescription rate
and duration of antibiotic treatment in days, days off
work and days with side-effects from medication within
14 days, and relapse rate from ARTI within 28 days after
randomisation.
Our hypothesis is that the clinical outcome for patients
with ARTI will be no worse under ProCT-guided treat-
ment, but patients with ProCT-guided treatment will have
lower total antibiotic use; specifically a 20% lower antibi-
otic prescription rate and a 20% shorter antibiotic dura-
tion compared to patients treated under the standard
approach.
Sample size considerations
This is a non-inferiority trial. We aim to show that on aver-
age ProCT-guided antibiotic management leads to at most
one day more with restrictions than a standard approach.
We consider a type I error rate of 5% and a type II error
rate of 10% (i.e. 90% power) appropriate in this situation.
In a previous trial in patients with acute respiratory tract
infections (ISRCTN57824788), the standard deviation in
the number of days with restrictions from ARTI was 4 days
for those patients prescribed antibiotics. Given this previ-
ous estimate of the variability in the primary outcome,
275 patients are needed per treatment group [44]. Allow-
ing for a loss to follow-up of 10% gives 306 patients per
treatment group, or a total of 612 patients. This sample
size will allow us to estimate the reduction in antibiotic
use between the two arms to within ± 6%.
With a maximum of 20 patients recruited per practice we
will probably need at least 35 participating general prac-
tices. To assess between-GP-variability in a sensitivity
analysis, we will need a minimum of 10 patients (prefera-
bly 15) recruited per practice.
Statistical analysis
With a non-inferiority trial, an intent-to-treat analysis is
not necessarily conservative. For the primary outcome, we
will need to provide several intent-to-treat analyses under
different assumptions about patients who do not com-
plete the trial, and a per-protocol analysis. Per-protocol
analyses are planned for all secondary outcomes [44].
All outcomes will be analysed by a generalised linear
model, assuming an appropriate distribution for each out-
come and using the same set of covariates. These covari-
ates will be: age, sex, education and a baseline score of the
degree of restricted activity reported by the patient. 95%
confidence intervals will be reported for the difference
between treatment groups.
For the primary outcome, the assumed distribution will
be normal; that is, analysis will be by multivariate linear
regression. As a sensitivity analysis, the GP will be added
to the model as a random effect and the model re-fit to the
data from all GPs with only one GP per practice and with
at least 10 patients per GP. Our experience from a previ-
ous trial (ISRCTN57824788) is that the difference
between GPs has little influence on patient reported
outcomes.
For secondary outcomes, assumed distributions will be
binomial (i.e. for prescription of antibiotics) or normal
(i.e. duration of antibiotic treatment). Duration of antibi-
otic treatment will be analysed only for those patients
who receive antibiotics. We will also report a confidence
interval for the difference in the antibiotic prescription
rate between treatment groups. As a sensitivity analysis,
we will repeat this calculation using a method appropriate
for a cluster sample, where each GP forms a cluster and
using only data from GPs with one GP per practice and
with at least 10 patients per GP.BMC Family Practice 2005, 6:34 http://www.biomedcentral.com/1471-2296/6/34
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Time plan for the study
Patient recruitment began in December 2004 and is
planned to continue until December 2005. By April 2005,
213 patients (35% of target) have been recruited into the
trial.
Discussion
The present trial is the first randomised controlled trial to
evaluate whether ProCT testing in a primary care setting
reduces antibiotic use for ARTI without compromising
patient relevant outcomes. In case of success, implement-
ing this new approach into daily practice could largely
improve the management of ARTI in primary care by
avoiding unnecessary antibiotic use and preventing anti-
biotic resistance.
Our trial may have some limitations. First, this is an open
intervention trial, and GPs may learn from their experi-
ence with ProCT testing and improve their clinical judge-
ment. We cannot control for this bias, but at least this bias
will be conservative for outcomes such as the antibiotic
prescription rate and the duration of antibiotic therapy.
Second, we expect to have recruited highly motivated pri-
mary care physicians, interested in the research question
and able to provide high quality data. Motivated, inter-
ested GPs might be more reluctant to prescribe antibiotics
for ARTI; thus they might consider patients for antibiotic
treatment which are on average sicker than patients con-
sidered by disinterested GPs. However, we believe that
ProCT-guided ARTI management will lead to a reduced
antibiotic use even in such a setting of motivated GPs and
the potential bias will be conservative. Third, while meas-
urement of ProCT at a central laboratory is not ideal for
routine primary care, there are still a considerable number
of general practices that send blood samples daily to a lab-
oratory for analysis of C-reactive protein or leucocytes.
Therefore this should also be feasible for ProCT until a
near-patient test, which is currently being developed,
becomes widely available.
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